Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of pBI-4 Plasmid Administered Via Intramuscular TriGrid™ Electroporation Delivery System for Treatment of Women With HPV16-Positive Grade 1 Cervical Intraepithelial Neoplasia or Persistent HPV16 Infection

NCT07809997 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT07809997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07809997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of pBI-4 Plasmid Administered Via Intramuscular TriGrid™ Electroporation Delivery System for Treatment of Women With HPV16-Positive Grade 1 Cervical Intraepithelial Neoplasia or Persistent HPV16 Infection
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2030
Enrollment
94 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia grade 1, human papillomavirus 16 infection